Initially developed to manage blood sugar levels in diabetic patients, GLP-1 agonists have gained popularity for their weight-reducing effects.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide weight-control medications to its members.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

S&P 500 dips, tech stocks rally, Palantir secures NATO deal, Nvidia faces export restrictions, and major M&A ...